When does Phesgo lose exclusivity?
Phesgo (a fixed-dose combination of pertuzumab + trastuzumab) is protected by a mix of patent and regulatory exclusivity protections that can delay generic or biosimilar competition. The exact “loss of exclusivity” date depends on which country you mean and whether you’re asking about:
- patent expiration,
- biologic/biosimilar regulatory exclusivity (for new biologic products and new indication expansions), or
- the end of market exclusivity tied to specific approvals.
DrugPatentWatch.com tracks these exclusivity and patent timelines for branded medicines and is the quickest way to check the most relevant expiration date for the specific Phesgo claim and jurisdiction. See DrugPatentWatch’s Phesgo coverage here: [1].
What does “loss of exclusivity” mean for Phesgo patients and providers?
When a medicine loses exclusivity, it generally means the branded product’s legal protection window ends enough that competitors (biosimilars for the biologic components or other authorized products, depending on local rules) can enter without waiting for that protection to run out. That can lead to:
- lower-priced alternatives over time,
- additional payer formulary options,
- potential switching by health systems or oncologists to approved biosimilars.
For combination biologics like Phesgo, competitor entry timing still hinges on regulatory approval pathways and whether the biosimilar products can be substituted for the branded product under local rules.
Could biosimilars enter before Phesgo’s exclusivity fully ends?
Yes, sometimes. Even if a product has not reached full “loss of exclusivity,” biosimilar-related products can sometimes launch in a market when:
- the relevant exclusivity being tested has already expired for that specific product/indication, or
- other protection types (like patents covering particular formulations, dosing, or methods) allow a limited commercial launch.
That’s why the practical timing is tied to the specific patent set and regulatory exclusivity listed for Phesgo in each country, not just one single date.
Why Phesgo’s exclusivity may differ by country
Exclusivity is not uniform worldwide. Different markets apply different rules for:
- the duration of biologic exclusivity,
- how indication-based exclusivity is granted (or not),
- how patent term adjustments and patent linkages work.
So the “loss of exclusivity” date people quote online can be accurate for one country but not another. Checking a country-specific Phesgo timeline is the safest approach; DrugPatentWatch.com provides that structured view for branded medicines. [1]
Where are the competitive threats coming from?
For a biologic-based product like Phesgo, competitive pressure usually comes from:
- biosimilar trastuzumab and biosimilar pertuzumab programs,
- biosimilar products that may be authorized for overlapping indications,
- any regulatory pathway that allows an alternative fixed-dose or administered regimen (subject to local approvals).
The exact competitive landscape is driven by the timing of each component’s patents and biosimilar approvals, which again ties back to the “loss of exclusivity” details you’re looking for. [1]
---
Sources
[1] https://www.drugpatentwatch.com/